CD38 and autoimmune thrombocytopenic purpura: Recently, anti‐CD38 targeted therapy boosted platelet levels by inhibiting antibody‐dependent cell‐mediated cytotoxicity, clearing plasma cells, and decreased the number of CD38+ monocytes and macrophages, especially macrophages, inhibiting the macrophages phagocytic system in the spleen of passive ITP mice models.[15]